Iterum Therapeutics (NASDAQ:ITRM) Trading Down 1.1% – Time to Sell?

Iterum Therapeutics PLC (NASDAQ:ITRM)’s share price fell 1.1% during trading on Tuesday . The company traded as low as $0.34 and last traded at $0.3502. 649,889 shares were traded during mid-day trading, a decline of 34% from the average session volume of 988,284 shares. The stock had previously closed at $0.3540.

Analysts Set New Price Targets

Several brokerages recently weighed in on ITRM. Wall Street Zen downgraded Iterum Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Iterum Therapeutics in a report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Iterum Therapeutics has an average rating of “Hold” and an average target price of $9.00.

Iterum Therapeutics Stock Down 1.1%

The stock’s 50-day moving average price is $0.45 and its 200 day moving average price is $0.66. The firm has a market cap of $18.66 million, a price-to-earnings ratio of -0.47 and a beta of 2.87.

Iterum Therapeutics (NASDAQ:ITRM) last released its earnings results on Friday, November 14th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.07). The company had revenue of $0.39 million during the quarter. On average, research analysts predict that Iterum Therapeutics PLC will post -0.86 EPS for the current year.

Institutional Trading of Iterum Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Virtu Financial LLC acquired a new position in shares of Iterum Therapeutics in the third quarter valued at $32,000. Jane Street Group LLC acquired a new stake in Iterum Therapeutics during the second quarter worth $92,000. Finally, OneDigital Investment Advisors LLC increased its holdings in Iterum Therapeutics by 18.6% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 191,000 shares of the company’s stock valued at $128,000 after buying an additional 30,000 shares during the period. 9.21% of the stock is currently owned by institutional investors.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance.

The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI).